Loading...
This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordThis document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Country's Decision or any other Communication
(DEC)
last updated: 13 Jul 2026
No
Commercial Release of the Vaccine composed of genetically modified microorganisms of biological risk class 1, "Bovela ® - Modified live vaccine against type 1 and type 2 bovine viral diarrhea" - Technical Opinion No. 4594/2015.
EN
10 Jun 2015
No
- Decision on LMOs for intentional introduction into the environment (according to Article 10 or domestic regulatory framework)
- Decision on LMOs for direct use as food or feed, or for processing (Article 11, LMOs-FFP)
No
Yes
-
Organization:Boheringer Ingelheim Química e Farmacêutica Ltda. ()Private sector (business and industry)Avenida das Nações Unidas, 14171, 18º andar - Torre B - Vila Gertrudes. 04794-000.São Paulo, São Paulo
04794-000, BrazilPhone: 55 11 4949-4700,Fax: 55 11 4949-4700,Website: http://www.boehringer-ingelheim.com.br/,
Yes
Yes
Yes
- LMOs for processing
No
Approval of the import and/or use of the LMO(s) without conditions
Yes
Yes
Yes
No
No
-
BCH-LMO-SCBD-110717-2 Living Modified Organism Bovela® VaccineBoheringer Ingelheim Química e Farmacêutica Ltda. | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
-
BCH-RA-BR-113493-1 Risk Assessment generated by a regulatory process Risk Assessment Bovela® Modified Live Vaccine against Type 1 and Type 2 Bovine Diarrhea VirusBovela® Vaccine | BVDV-1, BVDV-2, Production of medical or pharmaceutical compounds (human or animal)
- Commercial release 4594-2015.pdf [ Portuguese ]
